Gilead Sciences (GILD) EBT (2009 - 2026)
Gilead Sciences' (GILD) quarterly EBT came in at $2.6 billion in Q1 2026, up 56.46% YoY from $1.6 billion in Q1 2025, and up 24.16% on a QoQ basis from $2.1 billion in Q4 2025.
Gilead Sciences (GILD) EBT (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of EBT data on file, last reported at $2.6 billion in Q1 2026.
- Quarterly EBT rose 56.46% year-over-year to $2.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 billion (up 57.19% YoY) and the FY2025 annual result came in at $9.8 billion, up 1319.71% from the prior year.
- EBT improved to $2.6 billion in Q1 2026, from $2.1 billion in the prior quarter.
- In the past five years, EBT ranged from a high of $3.6 billion in Q3 2025 to a low of -$4.5 billion in Q1 2024.
- A 5-year average of $1.5 billion and a median of $2.0 billion in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT surged 955.26% — and 2024, when it slumped 445.08%.
- Tracing GILD's EBT over 5 years: stood at $2.0 billion in 2022, then decreased by 18.61% to $1.7 billion in 2023, then soared by 31.09% to $2.2 billion in 2024, then retreated by 4.11% to $2.1 billion in 2025, then rose by 24.16% to $2.6 billion in 2026.
- The last three EBT figures came in at $2.6 billion (Q1 2026), $2.1 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 6.75 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 4.28 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -683.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.27 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.80 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.77 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -653.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 474.95 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.25 Bn |
| Mar 31, 2026 | 2.58 Bn |
| Dec 31, 2025 | 2.08 Bn |
| Sep 30, 2025 | 3.64 Bn |
| Jun 30, 2025 | 2.43 Bn |
| Mar 31, 2025 | 1.65 Bn |
| Dec 31, 2024 | 2.17 Bn |
| Sep 30, 2024 | 956.00 Mn |
| Jun 30, 2024 | 2.05 Bn |
| Mar 31, 2024 | -4.49 Bn |
| Dec 31, 2023 | 1.65 Bn |
| Sep 30, 2023 | 2.32 Bn |
| Jun 30, 2023 | 1.59 Bn |
| Mar 31, 2023 | 1.30 Bn |
| Dec 31, 2022 | 2.03 Bn |
| Sep 30, 2022 | 2.43 Bn |
| Jun 30, 2022 | 1.50 Bn |
| Mar 31, 2022 | -152.00 Mn |
| Dec 31, 2021 | 759.00 Mn |
| Sep 30, 2021 | 3.44 Bn |